U.S. Markets open in 8 hrs 21 mins

Verona Pharma to Present at Upcoming Investor Conferences

LONDON, May 30, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (VRP.L) (VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that Company Management will present at the following upcoming investor conferences:

Event: Jefferies 2018 Global Healthcare Conference
Presenter: Jan-Anders Karlsson, Chief Executive Officer and Executive Director
Date: June 6, 2018
Time: 1:30 PM EDT
Location: New York, NY

Event: JMP Life Science Conference
Presenter: Piers Morgan, Chief Financial Officer
Date: June 20, 2018
Time: 12:30 PM EDT
Location: New York, NY

For more information please visit www.veronapharma.com

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma`s product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has shown clinically meaningful and statistically significant improvements in lung function and clinical symptoms as compared to placebo, and has shown statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators as compared to such bronchodilators administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and potentially asthma.

For further information, please contact:

Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
   
Stifel Nicolaus Europe Limited (Nominated Adviser 
and UK Broker)
Tel: +44 (0) 20 7710 7600
Stewart Wallace / Jonathan Senior / Ben Maddison  
   
FTI Consulting (UK Media and Investor enquiries) Tel: +44 (0)20 3727 1000
Simon Conway / Natalie Garland-Collins veronapharma@fticonsulting.com
   
ICR, Inc. (US Media and Investor enquiries)  
James Heins Tel: +1 203-682-8251
James.Heins@icrinc.com
Stephanie Carrington Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Verona Pharma plc via GlobeNewswire

HUG#2196055